comparemela.com

Latest Breaking News On - Itm isotope technologies munich se - Page 1 : comparemela.com

ITM, Helmholtz Munich and University Hospital Münster

A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of.

Ben orzelekSteffen schusterKathleen noonan gerrit siegersThomas bauerReinhard zeidlerDeutsches forschungszentrumWalter stummerVerena cosciaUmwelt gmbNuclear medicineDepartment of neurosurgeryUniversity hospitalCorporate communicationsHelmholtz associationNovel therapeutic approachHelmholtz munich

ITM Appoints Dr Mark Harfensteller as Member of its

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the.

Gerrit siegersA societas europaeaSebastian marxSteffen schusterBen orzelekMark harfenstellerKlaus maleckCanadian nuclear laboratoriesTechnical university of munichCorporate communicationsGroup as head of engineeringInstitute of machine toolsChief operating officerManaging directorIsotopes gmbhGood manufacturing practice

ITM Announces Operational Readiness for NOVA Facility, the

Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly.

Gerrit siegersSteffen schusterBen orzelekBavarian environment agency lfCorporate communicationsRadioactive material handling licenseRadiopharmaceutical therapyBavarian environment agencyTechnologies munichItm isotope technologies munich seTm seLutetium 177Operational readinessProduction site

ITM Enters Cooperation Agreement with Paul Scherrer

Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) .

Julia hofmann svenjaSteffen schusterBen orzelekRoger schibliCorporate communicationsEuropean journal of nuclear medicineGroup leaderHead of the centerResearch group leaderPaul scherrer instituteTargeted radionuclide therapyScherrer instituteRadiopharmaceutical scienceRadionuclide therapyTechnologies munichEuropean journal

ITM to Present Phase III COMPOSE Poster and Host Satellite

Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the.

United statesUppsala lanComunidad autonoma de catalunaJaume capdevilaBen orzelekJulia hofmann svenjaWolfgang weberAldo scarpaHeloisa soaresUppsala universityHospital trust of veronaHebron university hospitalUniversity of utahEuropean neuroendocrine tumor societyTechnical university of munichCorporate communications

vimarsana © 2020. All Rights Reserved.